Year: 2021
Type: review
Abstract: The use of T cells reactive with intracellular tumor-associated or tumor-specific antigens has been a promising strategy for cancer immunotherapies in the past three decades, but the approach has been constrained by a limited understanding of the T cell receptor's (TCR) complex functions and specificities. Newer TCR and T cell-based approaches are in development, including engineered adoptive T cells with enhanced TCR affinities, TCR mimic antibodies, and T cell-redirecting bispecific agents. These new therapeutic modalities are exciting opportunities by which TCR recognition can be further exploited for therapeutic benefit. In this review we summarize the development of TCR-based therapeutic strategies and focus on balancing efficacy and potency versus specificity, and hence, possible toxicity, of these powerful therapeutic modalities.
Source: Frontiers in Immunology
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,950
Awards: G1358310196, Immunobiology of Allogeneic Hematopoietic Cell Transplantation, A High Throughput Method to Determine the Target of T Cell Receptors, Improving specificity of therapeutic antibodies for cancer., G4621852861, Cancer Pharmacology, Cancer Center Support Grant, Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.
OpenAlex ID: W3121804747